Moreover, Plac1 expression showed important prognostic significance: In the in‐house TMA cohort, patients with higher Plac1 expression levels showed shorter overall survival (OS) (p = 0.0483) (Figure 1F), which was consistent with our previous study.[24] For advanced HNSCC patients, immune checkpoint inhibitor (ICI) therapy is one of the most important therapeutics. This evidence concerns the gene PLAC1 and head and neck squamous cell carcinoma.